1. Home
  2. SPE vs TNYA Comparison

SPE vs TNYA Comparison

Compare SPE & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Special Opportunities Fund Inc

SPE

Special Opportunities Fund Inc

N/A

Current Price

$13.57

Market Cap

141.1M

Sector

Finance

ML Signal

N/A

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

N/A

Current Price

$0.70

Market Cap

168.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPE
TNYA
Founded
1993
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.1M
168.2M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
SPE
TNYA
Price
$13.57
$0.70
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.33
AVG Volume (30 Days)
24.7K
1.9M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
8.55%
N/A
EPS Growth
N/A
54.96
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.02
$0.53
52 Week High
$15.99
$2.35

Technical Indicators

Market Signals
Indicator
SPE
TNYA
Relative Strength Index (RSI) 57.17 44.87
Support Level $13.51 $0.66
Resistance Level $13.71 $0.82
Average True Range (ATR) 0.15 0.03
MACD 0.01 0.00
Stochastic Oscillator 70.27 61.17

Price Performance

Historical Comparison
SPE
TNYA

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Share on Social Networks: